公开(公告)号：US3027363A

公开(公告)日：1962-03-27

申请号：US53601755

申请日：1955-09-22

Applicant: UPJOHN CO

Inventor： WARNER DONALD T

IPC: C07C307/02

CPC classification number: C07C307/02

公开(公告)号：US3894000A

公开(公告)日：1975-07-08

申请号：US38085073

申请日：1973-07-19

Applicant: UPJOHN CO

Inventor： WECHTER WILLIAM J ,  WARNER DONALD T

IPC: C07H19/06 ,  C07D51/52

CPC classification number: C07H19/06

Abstract: Novel 2''-0-, 3''-0-, 2'',3''-di-0-, 2'',5''-di-0- and 3'',5''-di-0esters of ara-cytidine and novel processes for their preparation are claimed. The novel 2''-0-esters (1) and 2'',5''-di-0-esters (11) are embraced by the formula

WHEREIN Y is selected from the group consisting of 1.

wherein R is a radical selected from the group consisting of aliphatic of from 1 through 20 carbon atoms, aromatic of from 6 through 10 carbon atoms, cage-type hydrocarbon of from 7 through 20 carbon atoms, monocyclic aliphatic of from 4 through 10 carbon atoms, araliphatic of from 7 through 12 carbon atoms and monocyclic heterocyclic of from 4 through 10 carbon atoms, including such radicals substituted by halogen, hydroxyl, carboxyl, nitro, alkoxyl or mercapto groups; 2.

wherein R'' is a radical selected from the group consisting of aliphatic of from 1 through 20 carbon atoms, aromatic of from 6 through 10 carbon atoms, araliphatic of from 7 through 12 carbon atoms, AND Z is selected from the group consisting of Y and hydrogen; and pharmaceutically acceptable acid addition salts thereof. The novel 3''-0-esters (III) and 3'',5''-di-0-esters (IV) are embraced by the formula

WHEREIN Z and Y are as given above, and pharmaceutically acceptable acid addition salts thereof. The novel 2'',3''-di-0-esters (V) are embraced by the formula

WHEREIN Y is as given above, and pharmaceutically acceptable acid addition salts thereof. The compounds of the above formulae are orally active sustainedrelease immunosuppressant and anti-neoplastic agents having the characteristics of the anti-leukemic compound ara-cytidine.

Abstract translation: ara-cytidine的新的2'-0-，3'-0-，2'，3'-二-O-，2'，5'-二-O-和3'，5'-二-O- 并要求其制备新颖的方法。 新的2'-O-酯（1）和2'，5'-二-O-酯（11）包括式WHEREIN Y选自由以下组成的组：O PARALLEL RC-，其中R为 选自1至20个碳原子的脂族基团，6至10个碳原子的芳族基团，7至20个碳原子的笼型烃基，4至10个碳原子的单环脂肪族基团， 7至12个碳原子和4至10个碳原子的单环杂环，包括被卤素，羟基，羧基，硝基，烷氧基或巯基取代的基团; 2.其中R'为选自1至20个碳原子的脂族基团，6至10个碳原子的芳族基团，7至12个碳原子的芳脂族基团，Z Z为 选自Y和氢; 及其药学上可接受的酸加成盐。